Home > Research > Publications & Outputs > Pericardial and mediastinal fat-associated lymp...

Electronic data

  • DSI-2023-0026.R1 AAM

    Accepted author manuscript, 2.24 MB, PDF document

    Available under license: CC BY: Creative Commons Attribution 4.0 International License

Links

Text available via DOI:

View graph of relations

Pericardial and mediastinal fat-associated lymphoid clusters are rapidly activated in an alkane-induced model of systemic lupus erythematosus

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Pericardial and mediastinal fat-associated lymphoid clusters are rapidly activated in an alkane-induced model of systemic lupus erythematosus. / Bentkowska, Karolina; Hardgrave, Alex; Iqbal, Nadia et al.
In: Discovery Immunology, Vol. 2, No. 1, kyad017, 25.10.2023.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Bentkowska K, Hardgrave A, Iqbal N, Gresty L, Marsden B, Macharia S et al. Pericardial and mediastinal fat-associated lymphoid clusters are rapidly activated in an alkane-induced model of systemic lupus erythematosus. Discovery Immunology. 2023 Oct 25;2(1):kyad017. Epub 2023 Sept 25. doi: 10.1093/discim/kyad017

Author

Bibtex

@article{bd67706980294416abf8ff41e5821812,
title = "Pericardial and mediastinal fat-associated lymphoid clusters are rapidly activated in an alkane-induced model of systemic lupus erythematosus",
abstract = "Summary Systemic lupus erythematosus (SLE) is an autoimmune disease predominated by auto-antibodies that recognise cellular components. Pleural involvement is the most common SLE-related lung disease. Natural antibodies are rapidly secreted by innate-like B cells following perturbation of homeostasis and are important in the early stages of immune activation. The serous cavities are home to large numbers of innate-like B cells present both within serous fluid and resident within fat-associated lymphoid clusters (FALCs). FALCs are important hubs for B-cell activation and local antibody secretion within the body cavities. Patients with SLE can develop anti-phospholipid antibodies and in rare situations develop alveolar haemorrhage. Utilising delivery of the hydrocarbon oil pristane in C57BL/6 mice as a model of SLE we identify a rapid expansion of pleural cavity B cells as early as day 3 after intra-peritoneal pristane delivery. Following pristane delivery, pericardial B1 B cells are proliferative, express the plasma-cell surface marker CD138, and secrete both innate and class-switched antibodies highlighting that this cavity niche may play an unrecognised role in the initiation of lupus pleuritis.",
keywords = "SLE, fat-associated lymphoid clusters, lupus, pleuritis, pristane",
author = "Karolina Bentkowska and Alex Hardgrave and Nadia Iqbal and Laura Gresty and Bethany Marsden and Sheila Macharia and Lucy Jackson-Jones",
year = "2023",
month = oct,
day = "25",
doi = "10.1093/discim/kyad017",
language = "English",
volume = "2",
journal = "Discovery Immunology",
issn = "2754-2483",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Pericardial and mediastinal fat-associated lymphoid clusters are rapidly activated in an alkane-induced model of systemic lupus erythematosus

AU - Bentkowska, Karolina

AU - Hardgrave, Alex

AU - Iqbal, Nadia

AU - Gresty, Laura

AU - Marsden, Bethany

AU - Macharia, Sheila

AU - Jackson-Jones, Lucy

PY - 2023/10/25

Y1 - 2023/10/25

N2 - Summary Systemic lupus erythematosus (SLE) is an autoimmune disease predominated by auto-antibodies that recognise cellular components. Pleural involvement is the most common SLE-related lung disease. Natural antibodies are rapidly secreted by innate-like B cells following perturbation of homeostasis and are important in the early stages of immune activation. The serous cavities are home to large numbers of innate-like B cells present both within serous fluid and resident within fat-associated lymphoid clusters (FALCs). FALCs are important hubs for B-cell activation and local antibody secretion within the body cavities. Patients with SLE can develop anti-phospholipid antibodies and in rare situations develop alveolar haemorrhage. Utilising delivery of the hydrocarbon oil pristane in C57BL/6 mice as a model of SLE we identify a rapid expansion of pleural cavity B cells as early as day 3 after intra-peritoneal pristane delivery. Following pristane delivery, pericardial B1 B cells are proliferative, express the plasma-cell surface marker CD138, and secrete both innate and class-switched antibodies highlighting that this cavity niche may play an unrecognised role in the initiation of lupus pleuritis.

AB - Summary Systemic lupus erythematosus (SLE) is an autoimmune disease predominated by auto-antibodies that recognise cellular components. Pleural involvement is the most common SLE-related lung disease. Natural antibodies are rapidly secreted by innate-like B cells following perturbation of homeostasis and are important in the early stages of immune activation. The serous cavities are home to large numbers of innate-like B cells present both within serous fluid and resident within fat-associated lymphoid clusters (FALCs). FALCs are important hubs for B-cell activation and local antibody secretion within the body cavities. Patients with SLE can develop anti-phospholipid antibodies and in rare situations develop alveolar haemorrhage. Utilising delivery of the hydrocarbon oil pristane in C57BL/6 mice as a model of SLE we identify a rapid expansion of pleural cavity B cells as early as day 3 after intra-peritoneal pristane delivery. Following pristane delivery, pericardial B1 B cells are proliferative, express the plasma-cell surface marker CD138, and secrete both innate and class-switched antibodies highlighting that this cavity niche may play an unrecognised role in the initiation of lupus pleuritis.

KW - SLE

KW - fat-associated lymphoid clusters

KW - lupus

KW - pleuritis

KW - pristane

U2 - 10.1093/discim/kyad017

DO - 10.1093/discim/kyad017

M3 - Journal article

VL - 2

JO - Discovery Immunology

JF - Discovery Immunology

SN - 2754-2483

IS - 1

M1 - kyad017

ER -